Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the 68 Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.

Autor: von Guggenberg E; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria irene.virgolini@i-med.ac.at elisabeth.von-guggenberg@i-med.ac.at., Uprimny C; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria., Klinger M; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria., Warwitz B; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria., Sviridenko A; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria., Bayerschmidt S; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria., di Santo G; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria., Virgolini IJ; Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria irene.virgolini@i-med.ac.at elisabeth.von-guggenberg@i-med.ac.at.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Jun; Vol. 64 (6), pp. 859-862. Date of Electronic Publication: 2023 Jan 19.
DOI: 10.2967/jnumed.122.264977
Abstrakt: PET/CT with the new 68 Ga-labeled minigastrin analog DOTA-dGlu-Ala-Tyr-Gly-Trp-( N -Me)Nle-Asp-1-Nal-NH 2 ( 68 Ga-DOTA-MGS5) was performed on patients with advanced medullary thyroid cancer (MTC) to evaluate cholecystokinin-2 receptor expression status. Methods: Six patients with advanced MTC underwent PET/CT with 68 Ga-DOTA-MGS5. From the images acquired 1 and 2 h after injection, preliminary data on the biodistribution and tumor-targeting properties were evaluated in a retrospective analysis. Results: In total, 87 lesions with increased radiotracer uptake considered malignant were detected (2 local recurrences, 8 lymph node lesions, 27 liver lesions, and 50 bone lesions). In general, radiotracer accumulation in lesions was higher at 2 h than at 1 h after injection (mean SUV max , 7.2 vs. 6.0, respectively; mean SUV mean , 4.4 vs. 3.6, respectively). Conclusion: The preliminary results clearly demonstrate the potential of 68 Ga-DOTA-MGS5 PET/CT in detecting local recurrence and metastases in patients with advanced MTC.
(© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze: MEDLINE
Externí odkaz: